Blog

Rasha Aboelhassan: By the end of the year, everyone is looking for achievements

Rasha Aboelhassan/LinkedIn

Dec 4, 2024, 18:33

Rasha Aboelhassan: By the end of the year, everyone is looking for achievements

Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, posted on LinkedIn:

“By the end of the year, everyone is looking for achievements.

((Do you think that eliminating chemotherapy from the first-line treatment of advanced urothelial cancer is an achievement?))

This was the main question in my conversation yesterday with my team.

The real achievement is making the right choice, to fit the right patient into the right treatment, striving for maximum effectiveness and minimum toxicity, including financial toxicity.

Discussing results of clinical trial EV-302:

((Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer))

My argument was: ((Although the risk of disease progression or death in the enfortumab vedotin-pembrolizumab group was 55% lower than the risk of disease progression in the chemotherapy group, we still needed careful patient selection because there’s still more challenges in adverse reactions:
Skin reactions, peripheral neuropathy, and hyperglycemia were the most challenging toxicities.))

My conclusion: By all means, the greatest breakthroughs come gradually, as EV-302 has beaten chemotherapy in the first-line treatment of advanced urothelial carcinoma.
we still waiting for real-world data.

Thanks for my team and MSD team for the fruitful interactive discussion.”

Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics. Rasha has been accepted as a member of staging and Prognostic Factors Group of lung cancer SPFG.